Table 2.
Patient characteristics and outcome
| Subject | Allo/ Auto | Age | Chemo | NK Manufacture | Dose ×107 NK/kg | Day 7 NK/μL (% donor) | Fold NK Day 7/Pre | Response | TTNT |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Auto | 73 | Bor/Cy/Flu | Frozen | 3.2 | NE | NE | PR (0) | 185 |
| 2 | Allo | 48 | Bor/Cy/Flu | Frozen | 3.4 | 9 (0%) | 0 | PD (20) Death (98) |
76 |
| 3 | Auto | 50 | Bor/Cy/Flu | Frozen | 2.2 | 82 | 1 | PD (20) | NE, LF |
|
| |||||||||
| 4 | Auto | 61 | Bor | Fresh Low IL2 |
6 | 512 | 37 | PD (23) | 79 |
| 5 | Allo | 64 | Bor/Cy/Flu | Fresh Low IL2 |
10 | 547 (92%) | 9 | NE Death (11) |
NA |
| 6 | Auto | 64 | Bor | Fresh Low IL2 |
8 | 438 | 5 | PD (12) | 48 |
| 7 | Auto | 68 | Bor | Fresh High IL2 |
10 | 5199 | 40 | PD (34) | 187 |
| 8 | Allo | 62 | Bor/Cy/Flu | Fresh High IL2 |
10 | 1855 (94%) | 21 | PD (32) Death (56) |
NA |
Subjects who received cryopreserved products are above the dashed line, those who received fresh products are below the dashed line. Autologous product recipients (Auto) below the dashed line were prepared with Bor without Cy/Flu. Absolute NK cell counts were obtained from PB samples. The absolute NK count was not evaluable for patient 1 due to low cell count, however the % NK cells and WBC count on day 7 was not higher than the baseline value. Fold NK change was calculated as the absolute number of NK cells in the blood on day 7 ÷ the number of NK cells pre-chemo. Allo, Allogeneic product recipients; Auto, Autologous product recipients; Bor, bortezomib; Cy, cyclophosphamide; Flu, fludarabine; PR, partial response (days since NK infusion); PD, progressing disease; TTNT, time to next treatment in days; NE, not evaluable; NA, not applicable; LF, lost to follow-up.